Quarterly report pursuant to Section 13 or 15(d)

Stock Warrants

v3.21.2
Stock Warrants
9 Months Ended
Sep. 30, 2021
Text Block [Abstract]  
Stock Warrants
10
. Stock Warrants
As of September 30, 2021 and December 31, 2020, the Company had warrants to purchase the underlying common stock outstanding as shown in the table below.
 
 
 
 
 
 
 
 
 
 
    
September 30,
2021
    
December 31,
2020
 
2020 Warrants
     8,819,904        8,842,464  
2017 Warrants
     1,599,645        1,599,645  
2016 Warrants
     —          1,400,000  
Pfizer Warrant
     505,617        505,617  
Other warrants (1)
     1,567        2,567  
    
 
 
    
 
 
 
Warrants to purchase common stock
     10,926,733        12,350,293  
    
 
 
    
 
 
 
Weighted-average exercise price per share
   $ 6.47      $ 9.14  
    
 
 
    
 
 
 
 
(1)
Other warrants are comprised of warrants issued prior to the Company’s initial public offering (“IPO”), generally in exchange for services rendered to the Company.
The following table summarizes information regarding the Company’s warrants outstanding at September 30, 2021:
 
 
 
 
 
 
 
 
 
 
Exercise Prices
  
Shares
Underlying
Outstanding
Warrants
    
Expiration Date
 
£
$10.00
     9,325,521        May 27, 2023  
> $10.00
£
$20.00
     1,599,645        July 25, 2022  
> $20.00
     1,567        October 17, 2021 – January 5, 2022  
    
 
 
          
       10,926,733